Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Fig. 1

Kaplan–Meier curves of overall survival (OS), distant metastasis-free survival (DMFS)and progression-free survival (PFS). The 1-year DMFS rate, PFS rate and OS rate were 59.9%, 48.7% and 84.2%, respectively (A). OS, DMFS and PFS curves according to durvalumab administration are shown in B-D

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us